Supreme review: will SCOTUS take on Amgen v Sandoz?

Signed into law by the Obama administration in 2009 and part of the Affordable Care Act, the Biologics Price Competition and Innovation Act (BPCIA) introduced a biosimilars pathway to the US. The new regulatory pathway brought with it a new problem: interpretation.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Attorney v examiner: Navigating patenting's AI tools ‘arms race’

Lewis Roca promotes tech expert to managing partner

Panitch Schwarze brings in molecular biologist

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

ITC concludes row over biotech lab equipment between US and German rivals

USPTO clarifies AI's role in patent eligibility

Supreme review: will SCOTUS take on Amgen v Sandoz?

Editor's picks

Editor's picks

More features